Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 7, 2025 | $0.34 | 2025-03-31 | 2025-03-31 |
| December 12, 2024 | $0.33 | 2024-09-30 | 2024-09-30 |
| July 8, 2024 | $0.29 | 2024-03-27 | 2024-03-28 |
| December 11, 2023 | $0.32 | 2023-09-28 | 2023-09-29 |
| July 10, 2023 | $0.31 | 2023-03-30 | 2023-03-31 |
Dividends Summary
- Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) has issued 13 dividend payments over the past 6 years
- The most recent dividend was paid 120 days ago, on July 7, 2025
- The highest dividend payed out to investors during this period was $0.43 per share
- The average dividend paid during this period was $0.36 per share.
Company News
Takeda Pharmaceutical has entered a multi-year research collaboration with Nabla Bio, utilizing their generative AI platform for antibody design, with potential payments exceeding $1 billion.
French biotech company EVerZom secured €10M in funding to develop exosome-based therapies, focusing on launching its first clinical trial for EVerGel™ in 2026 to treat Crohn's perianal fistulas.
Protagonist Therapeutics reported Q2 2025 financial results, highlighting progress in clinical pipeline with rusfertide and icotrokinra drug candidates, while experiencing lower-than-expected revenue but maintaining strong cash reserves through 2028.
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.